A trial of 2-hydroxyoleic acid (2-OHOA) for people with a brain tumour or solid tumour that has spread (2-OHOA study)

Cancer type:

All cancer types

Status:

Results

Phase:

Phase 1

This trial looked 2-hydroxyoleic acid (2-OHOA) for people who had a certain type of brain tumour or a solid tumour. 

The type of brain tumour is called a glioma

A solid tumour Open a glossary item is any type of cancer apart from leukaemia Open a glossary item or lymphoma Open a glossary item.

More about this trial

To treat cancers doctors can use:
But sometimes cancers continue to grow despite having all these standard treatments. Researchers are always looking at new ways to treat people in this situation. 
 
In this trial, they looked at a drug called 2-OHOA.
 
2-OHOA comes from a substance that is related to olive oil. We knew from laboratory research that 2-OHOA stops the growth of cancer cells.
 
This trial was the first time 2-OHOA had been tested in people with cancer.
 
The aims of the trial were to:
  • find the best dose of 2-OHOA
  • learn about the side effects
  • see what happened to 2-OHOA in the body
  • find out how well 2-OHOA worked for different types of cancer

Summary of results

The trial team found the best dose of 2-OHOA to give. 
 
The trial was open to people to join between June 2013 and March 2016. These results were presented at a conference in 2017.
 
About this trial
This was a phase 1 trial. 54 people took part.
 
The first few people had a low dose of 2-OHOA. If they didn’t have bad side effects the next few had a higher dose. And so on until the best dose of 2-OHOA was found. 
 
Results
The best dose of 2-OHOA is 4g of the liquid suspension taken by mouth three times a day. It can be taken with food or not. 
 
Results for glioma 
Of the 27 people who had 2-OHOA, 21 had at least 1 cycle of treatment (3 weeks).
 
When the team looked at how well 2-OHOA had worked for people with glioma they found that for: 
  • 1 person it had shrunk considerably (a partial response) and this lasted for more than 2½ years
  • 3 people it had stayed the same (stable disease) for at least 6 weeks 
  • 4 people it had stayed the same for 6 months or more 
Results for solid tumours
24 people of the 27 people treated had at least 1 cycle of 2-OHOA (3 weeks). 
 
When they looked at how well it worked for those with solid tumours they found that for: 
  • 1 person their solid tumour had stayed the same for about 10 months (45 weeks)
  • 1 person their solid tumour had stayed the same for 3 months
  • 1 person their solid tumour had stayed the same for 5 months
  • 2 people their solid tumour had stayed the same for 2 months
The most common side effects were:
  • diarrhoea
  • feeling or being sick
Conclusion
The team found the best dose of 2-OHOA to give. And concluded the results for people with glioma support a phase 2 trial being done for this group of people. 
 
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) but may not have been published in a medical journal.  The figures we quote above were provided by the research team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Johann de Bono

Supported by

Experimental Cancer Medicine Centre (ECMC)
Lipopharma Therapeutics SL

Freephone 0808 800 4040

Last review date

CRUK internal database number:

11681

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think